Volume 10, Issue 3 (2024)
IEM 2024, 10(3): 223-235 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Chaabba Y, Gdoura M, Ernandes H, Jelassi I, Masmoudi A. Update on Age-Specific Rubella Seropositivity Rates among Pregnant Women 12 Years after Vaccine Introduction in Tunisia. IEM 2024; 10 (3) :223-235
URL: http://iem.modares.ac.ir/article-4-75603-en.html
URL: http://iem.modares.ac.ir/article-4-75603-en.html
1- Laboratory of Clinical Biology, Center of Maternity and Neonatology of Tunis, Tunisia. Faculty of Pharmacy of Monastir, University of Monastir, Monastir 5000, Tunisia. Research Laboratory ''Transmissible Diseases and Biologically Active Substances'' LR99ES27, Faculty of Pharmacy of Monastir, University of Monastir, Monastir 5000, Tunisia
2- Faculty of Pharmacy of Monastir, University of Monastir, Monastir 5000, Tunisia. Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, University Tunis El Manar, Tunis 1002, Tunisia. Research Laboratory ''Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health'' LR20IPT02, Institut Pasteur de Tunis, University Tunis El Manar, Tunis 1002, Tunisia ,Mariem.gdoura@Pasteur.tn
3- Department of Infectious Disease, Mohamed Taieb Kassab Institut of Orthopedics, Tunisia. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1002, Tunisia
4- Laboratory of Clinical Biology, Center of Maternity and Neonatology of Tunis, Tunisia. Faculty of Pharmacy of Monastir, University of Monastir, Monastir 5000, Tunisia.
2- Faculty of Pharmacy of Monastir, University of Monastir, Monastir 5000, Tunisia. Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, University Tunis El Manar, Tunis 1002, Tunisia. Research Laboratory ''Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health'' LR20IPT02, Institut Pasteur de Tunis, University Tunis El Manar, Tunis 1002, Tunisia ,
3- Department of Infectious Disease, Mohamed Taieb Kassab Institut of Orthopedics, Tunisia. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1002, Tunisia
4- Laboratory of Clinical Biology, Center of Maternity and Neonatology of Tunis, Tunisia. Faculty of Pharmacy of Monastir, University of Monastir, Monastir 5000, Tunisia.
Abstract: (902 Views)
Background: Assessment of rubella immunity coverage relies on regular updates. This study aimed to determine the age-specific seropositivity rates among a large cohort of pregnant women approximately 12 years after vaccine introduction in Tunisia, where serosurveys are both old and scarce.
Materials & Methods: A prospective cohort study was conducted on pregnant women referring to the Maternity and Neonatology Center of Tunis in 2017. Eligible and consenting participants underwent blood sampling twice with a 15-day interval to detect and measure rubella-specific IgG and IgM antibodies. Demographic and obstetric data were also gathered.
Findings: A total of 800 participants with a mean age of 30.6±5 years (range: 17-48) were enrolled in this study. The overall seropositivity rate was 90.4% (n=723) (95%CI: 88.3-92.4). Also, 77 (9.6%) (95%CI: 7.6-11.7) participants were seronegative, among them 36 cases were in the first trimester of their pregnancy. The WHO minimum rubella immunization threshold of 95% was achieved for the first time in the 12-year-old vaccination program target population (96%) (95%CI: 92-99.8). No significant association was found between seropositivity rates and age, geographic origin, occupation, gestational age at the time of enrollment, parity, and abortion history (p> .05), but a significant association was found with educational levels.
Conclusion: Pregnant women vaccinated at the age of 12 showed a high immunization rate. Next decades would witness the elimination of rubella virus circulation as well as congenital rubella syndrome.
Materials & Methods: A prospective cohort study was conducted on pregnant women referring to the Maternity and Neonatology Center of Tunis in 2017. Eligible and consenting participants underwent blood sampling twice with a 15-day interval to detect and measure rubella-specific IgG and IgM antibodies. Demographic and obstetric data were also gathered.
Findings: A total of 800 participants with a mean age of 30.6±5 years (range: 17-48) were enrolled in this study. The overall seropositivity rate was 90.4% (n=723) (95%CI: 88.3-92.4). Also, 77 (9.6%) (95%CI: 7.6-11.7) participants were seronegative, among them 36 cases were in the first trimester of their pregnancy. The WHO minimum rubella immunization threshold of 95% was achieved for the first time in the 12-year-old vaccination program target population (96%) (95%CI: 92-99.8). No significant association was found between seropositivity rates and age, geographic origin, occupation, gestational age at the time of enrollment, parity, and abortion history (p> .05), but a significant association was found with educational levels.
Conclusion: Pregnant women vaccinated at the age of 12 showed a high immunization rate. Next decades would witness the elimination of rubella virus circulation as well as congenital rubella syndrome.
Article Type: Original Research |
Subject:
Virology
Received: 2024/06/12 | Accepted: 2024/08/7 | Published: 2024/08/20
Received: 2024/06/12 | Accepted: 2024/08/7 | Published: 2024/08/20
References
1. Walker PJ, Siddell SG, Lefkowitz EJ, Mushegian AR, Dempsey DM, Dutilh BE, et al. Changes
2. 326
3. to virus taxonomy and the international code of virus classification and nomenclature ratified by the
4. 327
5. International Committee on Taxonomy of Viruses. Arch Virol. 2019;164(9):2417-29. [DOI:10.1007/s00705-019-04306-w] [PMID]
6. 328
7. Winter AK, Moss WJ. Rubella. Lancet. 2022;399(10332):1336-46. [DOI:10.1016/S0140-6736(21)02691-X] [PMID]
8. 329
9. Gregg NM. Congenital cataract following German measles in the mother, 1941. Aust N Z J [DOI:10.1007/978-94-011-6621-8_22]
10. 330
11. Ophthalmol. 1991;19(4):267-76. [DOI:10.1016/0168-8510(91)90017-R]
12. 331
13. Grillner L, Forsgren M, Barr B, Böttiger M, Danielsson L, De Verdier C. Outcome of rubella
14. 332
15. during pregnancy with special reference to the 17th-24th weeks of gestation. Scand J Infect Dis.
16. 333
17. 1983;15(4):321-5.
18. 334
19. World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec.
20. 335
21. 2020;95(27):301-24.
22. 336
23. Vynnycky E, Adams EJ, Cutts FT, Reef SE, Navar AM, Simons E, et al. Using seroprevalence
24. 337
25. and immunisation coverage data to estimate the global burden of congenital rubella syndrome, 1996-
26. 338
27. 2010: A systematic review. PloS One. 2016;11(3):e0149160. [DOI:10.1371/journal.pone.0149160] [PMID] []
28. 339
29. 16
30. 17
31. Pandolfi E, Gesualdo F, Rizzo C, Bella A, Agricola E, Mastroiacovo P, et al. Global
32. 340
33. seroprevalence of rubella among pregnant and childbearing age women: A meta-analysis. Eur J Public
34. 341
35. Health. 2017;27(3):530-7. [DOI:10.1016/j.paed.2017.07.004]
36. 342
37. World Health Organization. Global measles and rubella strategic plan: 2012. Geneva: World
38. 343
39. Health Organization; 2012.
40. 344
41. Messedi E, Fki-Berrajah L, Gargouri S, Chouikha A, Chaari A, Bouaziz M, et al. Clinical,
42. 345
43. epidemiological, and molecular aspects of rubella outbreak with high number of neurological cases,
44. 346
45. Tunisia 2011-2012. J Clin Virol. 2014;61(2):248-54. [DOI:10.1016/j.jcv.2014.07.003] [PMID]
46. 347
47. National Committee for Clinical Laboratory Standards. NCCLS document I/LA6-A: Detection
48. 348
49. and quantitation of rubella IgG antibody: Evaluation and performance criteria for multiple component
50. 349
51. test products, specimen handling, and use of test products in the clinical laboratory; Approved guideline.
52. 350
53. Wayne, PA: NCCLS: 1997.
54. 351
55. World Health Organization. Women's health. Geneva: World Health Organization; 2024.
56. 352
57. Boubaker SH, Ben Yahia A, Bahri O, Triki H. Rubella infection in children and teenagers in
58. 353
59. Tunisia. Pathol Biol. 2004;52(1):11-5.
60. 354
61. Bchir A, Soltani MS, Chakroun M, Kheder M, Jebara H, Ennigrou' S. Receptivity to rubella
62. 355
63. among pregnant females in Monastir (Tonesia). Med Mal Infect. 1992;22(11):919-22. [DOI:10.1016/S0399-077X(05)80630-4]
64. 356
65. Jemini L, Bchir A, Faurant C, Heyer F, Braham MS, Ayachi S, et al. Toxoplasmosis and rubella
66. 357
67. in Sousse: A sero-epidemiologic study in a school environment. Tunis Med. 1986;64(8-9):679-82.
68. 358
69. Nabli B. Seroepidemiology of rubella in Tunisia. Bull World Health Organ. 1970;42(6):891-6.
70. 359
71. 17
72. 18
73. Hannachi N, Marzouk M, Harrabi I, Ferjani A, Ksouri Z, Ghannem H, et al. Seroprevalence of
74. 360
75. rubella virus, varicella zoster virus, cytomegalovirus, and parvovirus B19 among pregnant women in
76. 361
77. the Sousse region, Tunisie. Bull Soc Pathol Exot. 2011;104(1):62-7. [DOI:10.1007/s13149-010-0119-z] [PMID]
78. 362
79. Chaabouni M, Messadi F, Fki L, Hammami A, Karray H. Rubella seroprevalence in Tunisian
80. 363
81. childbearing women two years after vaccination program introduction. Pathol Biol. 2012;60(3):170-3.
82. 364
83. Ben Haj Khalifa A, Berriri S, Kheder M. Seroprevalence of rubella among the young female
84. 365
85. healthcare personnel in the Mahdia Sfar teaching hospital, Tunisie. Med Mal Infect. 2011;41(9):493-4. [DOI:10.1016/j.medmal.2009.10.015] [PMID]
86. 366
87. Messedi E, Fki-Berrajah L, Gargouri S, Chouikha A, Chaari A, Bouaziz M, et al. Clinical
88. 367
89. epidemiological and molecular aspects of rubella outbreak with high number of neurological cases,
90. 368
91. Tunisia 2011-2012. J Clin Virol. 2014;61(2):248-54. [DOI:10.1016/j.jcv.2014.07.003] [PMID]
92. 369
93. Chabchoub I, Mejdoub I, Maalej B, Abid D, Aloulou H, Kamoun T, et al. Congenital rubella
94. 370
95. still exists in Tunisia! Arch Pediatr. 2011;18(11):1191-5.
96. 371
97. Merdassi A, Limaiem R, Turki F, Chaker N, Falfoul Y, Mghaieth F, et al. Ophthalmologic
98. 372
99. manifestations of congenital rubella. Arch Pediatr. 2011;18(8):870-3.
100. 373
101. Alaoui HL, Seffar M, Kassouati J, Zouaki A, Kabbaj H. Rubella seroprevalence among pregnant
102. 374
103. women in the region of Rabat, Morocco: A cross-sectional study. BMJ Open. 2023;13(6):e067842. [DOI:10.1136/bmjopen-2022-067842] [PMID] []
104. 375
105. Suárez-Ognio L, Adrianzén A, Ortiz A, Martínez C, Whittembury A, Cabezudo E, et al. A
106. 376
107. rubella serosurvey in postpartum women in the three regions of Peru. Rev Panam Salud Publica.
108. 377
109. 2007;22(2):110-7.
110. 378
111. Linguissi LS, Nagalo BM, Bisseye C, Kagoné TS, Sanou M, Tao I, et al. Seroprevalence of
112. 379
113. toxoplasmosis and rubella in pregnant women attending antenatal private clinic at Ouagadougou,
114. 380
115. Burkina Faso. Asian Pac J Trop Med. 2012;5(10):810-3. [DOI:10.1016/S1995-7645(12)60148-5] [PMID]
116. 381
117. 18
118. 19
119. Marchi S, Viviani S, Montomoli E, Trombetta CM. Elimination of congenital rubella: A
120. 382
121. seroprevalence study of pregnant women and women of childbearing age in Italy. Hum Vaccines
122. 383
123. Immunother. 2020;16(4):895-8. [DOI:10.1038/s41567-020-1023-5]
124. 384
125. Meng Q, Luo J, Li L, Shi W, Yu J, Shen Y, et al. Rubella seroprevalence among pregnant
126. 385
127. women in Beijing, China. BMC Infect Dis. 2018;18(1):1-5. [DOI:10.1186/s12879-018-3032-x] [PMID] []
128. 386
129. Adam O, Makkawi T, Kannan A, Osman ME. Seroprevalence of rubella among pregnant
130. 387
131. women in Khartoum state, Sudan. East Mediterr Health J. 2013;19(9):812-5. [DOI:10.26719/2013.19.9.812] [PMID]
132. 388
133. Shih CT, Chang YC, Wang HL, Lin CC. Comparing the rubella seronegativity in pregnant
134. 389
135. women who received one dose of rubella vaccine at different ages in Taiwan. Vaccine.
136. 390
137. 2016;34(40):4787-91.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |